0001189727-19-000004.txt : 20190308
0001189727-19-000004.hdr.sgml : 20190308
20190308132032
ACCESSION NUMBER: 0001189727-19-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190306
FILED AS OF DATE: 20190308
DATE AS OF CHANGE: 20190308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BURCAR ALISON D
CENTRAL INDEX KEY: 0001189727
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34634
FILM NUMBER: 19668531
MAIL ADDRESS:
STREET 1: C/O ICU MEDICAL INC
STREET 2: 951 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92673
FORMER NAME:
FORMER CONFORMED NAME: BRUMMETT BURCAR ALISON
DATE OF NAME CHANGE: 20020916
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ICU MEDICAL INC/DE
CENTRAL INDEX KEY: 0000883984
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 330022692
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92763-6212
BUSINESS PHONE: 949-366-2183
MAIL ADDRESS:
STREET 1: 951 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92763-6212
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2019-03-06
0
0000883984
ICU MEDICAL INC/DE
ICUI
0001189727
BURCAR ALISON D
951 CALLE AMANECER
SAN CLEMENTE
CA
92673
0
1
0
0
Vice President and Gen'l Mgr.
Common Stock
2019-03-06
4
M
0
10929
0.0
A
11699
D
Common Stock
2019-03-06
4
F
0
5163
0.0
D
6536
D
Common Stock
2019-03-06
4
M
0
3643
0.0
D
2019-03-06
Common Stock
10929
0
D
These Securities are Performance-based Restricted Stock Units (PRSU).
There is neither a purchase price nor an exercise price for the PRSUs.
Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.
These PRSUs were granted on February 5, 2016. The vesting for these PRSUs is dependent upon the achievement of performance criteria related to the Company's fiscal year 2018 Adjusted EBITDA per share CAGR in comparison to the fiscal year 2015 Adjusted EBITDA per weighted average basic share. The reporting person may potentially earn 100% to 300% of the target award amount originally reported on the date of grant.
By: Alejandro Parras, Attorney-In-Fact For: Alison D. Burcar
2019-03-08